Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP raised its stake in Humacyte, Inc. (NASDAQ:HUMA) by 43.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,875 shares of the company’s stock after buying an additional 12,905 shares during the quarter. Dark Forest Capital Management LP’s holdings in Humacyte were worth $217,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in Humacyte in the fourth quarter valued at about $50,000. Petros Family Wealth LLC acquired a new stake in shares of Humacyte during the fourth quarter worth about $50,000. Brookstone Capital Management acquired a new stake in shares of Humacyte during the fourth quarter worth about $56,000. ACT Wealth Management LLC acquired a new stake in shares of Humacyte during the fourth quarter worth about $57,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Humacyte during the fourth quarter worth about $62,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Stock Performance

HUMA stock opened at $1.43 on Wednesday. The company’s 50 day moving average price is $2.27 and its 200 day moving average price is $3.84. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.97. The firm has a market capitalization of $221.82 million, a price-to-earnings ratio of -1.07 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to analysts’ expectations of $0.64 million. Equities analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analysts Set New Price Targets

HUMA has been the topic of several research reports. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. Benchmark reissued a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $13.71.

Insider Buying and Selling at Humacyte

In related news, Director Kathleen Sebelius purchased 50,000 shares of the company’s stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares of the company’s stock, valued at approximately $120,393.24. This trade represents a 121.34 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Dale A. Sander purchased 20,000 shares of the company’s stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares of the company’s stock, valued at $62,118. The trade was a 97.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 83,993 shares of company stock worth $118,224 over the last three months. Insiders own 11.20% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.